WA-SPIE
17.12.2020 17:07:15 CET | Business Wire | Press release
SPIE Photonics West , which normally convenes in San Francisco, will be held as an interactive, virtual conference 6-11 March 2021. North America’s largest optics and photonics technology event – with its popular BiOS, LASE, and OPTO conferences – held by SPIE, the international society for optics and photonics , also includes two digital exhibitions and the industry-focused Quantum West. Registration for SPIE Photonics West will open 5 January.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005110/en/
In addition to SPIE Photonics West, the following SPIE 2021 conferences will also be held via the organization’s digital-forum platform: SPIE Advanced Lithography ; SPIE Medical Imaging ; SPIE AR/VR/MR ; and SPIE Smart Structures + Nondestructive Evaluation .
“The SPIE Digital Forum platform was developed to help people share results and make connections during the pandemic, and we’ve continued to fine-tune our virtual platform and digital offerings throughout this year,” says SPIE CEO Kent Rochford. “We’ll be implementing the latest improvements during Photonics West and are excited to release them to our attendees, presenters, and exhibitors. These forums, as always, ensure the professional discussion, innovation sharing, and networking opportunities that the SPIE community values and relies on to advance its research, product development, and engineering collaborations.”
"It's been a challenging year for our entire community, and I know that I am not alone in my desire to meet in person to exchange ideas, research, technological advances, and new products," says 2020 SPIE President John Greivenkamp. "We are hopeful of being able to gather in person later in 2021. In the meantime, I invite you to join us online at one or more of these dynamic conferences and look forward to seeing you there."
Each year, SPIE Photonics West showcases the latest in applications, technologies, and discoveries in optics and photonics, with three major conference tracks: BiOS, highlighting new research in biophotonics, biomedical optics, and applications of medical imaging; LASE, with its focus on the laser industry and applications; and OPTO, showcasing optoelectronics, photonic materials, and related devices. In addition, the symposium is introducing a new conference, highlighting photonics research and technologies addressing COVID-19 . Photonics West will also feature a Digital Marketplace with product demos showcasing the latest in optics and photonics technologies and opportunities to connect with the industry’s leading suppliers and companies.
The SPIE Digital Forums will offer a convenient, high-quality, and timely way for researchers, engineers, and government and industry leaders in the photonics community to share emerging research, new results, and technological advances with their peers. The SPIE online format makes presentations and discussion accessible during the Forum in whatever time zone is convenient for the participant and in any order. In addition, the Digital Forums will include networking opportunities, live plenary sessions, and special events. All conference presentations and manuscripts will be accessible after the conference via the SPIE Digital Library . Registration and pricing information is available on each event webpage.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5.8 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005110/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 21:00:00 CEST | Press release
Proposed acquisition extends Boomi’s AI gateway capabilities, enabling enterprises to govern massive volumes of traffic for production-ready AI Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, securi
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 19:27:00 CEST | Press release
BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the classApproval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, a
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 16:30:00 CEST | Press release
Orchestration capabilities simplify workflows, while advanced agent connectivity and an enhanced context layer activate data and scale AI Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this visio
Boomi and Red Hat Collaborate on Production-Ready Agentic AI13.5.2026 16:30:00 CEST | Press release
Companies team to deliver a unified, enterprise-scale agentic stack to help organizations with managing data sovereignty and optimizing AI costs Boomi, the data activation company for AI, and Red Hat, the world’s leading provider of open source solutions, today announced a strategic collaboration to deliver a single, integrated stack for deploying agentic AI at scale. For many organizations, building production AI today means assembling numerous disconnected vendor choices spanning agent builders, orchestration tools, governance platforms, model providers, integration middleware, and security infrastructure, which can lead to data leaks and unpredictable costs. Boomi and Red Hat are working together to simplify AI innovation for customers by bringing together Boomi’s Agentstudio with the enterprise-grade power of Red Hat AI. This makes it easier for organizations to build agents that solve real business problems while supporting corporate standards for sovereignty, infrastructure flexi
Boomi and Couchbase Partner to Power Enterprise AI Agents with Trusted Recollection, Connectivity, and Governance13.5.2026 16:30:00 CEST | Press release
Partnership enables customers to accelerate AI agents from pilot to production with accuracy, performance, and control by combining Boomi's connectivity, agent runtime, and governance with Couchbase's operational data platform Boomi, the data activation company for AI, and Couchbase, Inc., the operational data platform for AI, today announced a partnership through which the two companies are collaborating closely to accelerate AI pilots to production. The companies will co-engineer solutions that give customers a production-ready foundation for agentic AI, combining Boomi's connectivity, runtime, and governance for AI agents with Couchbase's scalable recollection and vector capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513350337/en/ Enterprises deploying AI agents today face a common challenge: while agents perform well in pilots, they struggle to scale due to inconsistent access to trusted context, recolle
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom